CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review,  July  2016

 

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy. Liu M1, Wang H2, Liu L3, Wang B4, Sun G5. J Transl Med. 2016 Jun 1;14(1):155. doi: 10.1186/s12967-016-0910-0.

miRNA-124 modulates lung carcinoma cell migration and invasion. Li Z, Wang X, Li W, Wu L, Chang L, Chen H. Int J Clin Pharmacol Ther. 2016 Jun 1. [Epub ahead of print]

A combinatorial strategy for treating KRAS-mutant lung cancer. Manchado E1, Weissmueller S1,2, Morris JP1, et al. Nature. 2016 Jun 22;534(7609):647-651. doi: 10.1038/nature18600. [Epub ahead of print]

Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adeno-carcinoma. DiBardino DM1, Saqi A2, Elvin JA3, Greenbowe J3, Suh JH3, Miller VA3, Ali SM3, Stoopler M4, Bulman WA5. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30133-4. doi: 10.1016/j.cllc.2016.05.017. [Epub ahead of print]

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Zhang H1, Shao H2, Golubovskaya VM3, Chen H1, Cance W3, Adjei AA1, Dy GK1. Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.190. [Epub ahead of print]

Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Singhal S1, Bhojnagarwala PS2, O’Brien S3, et al. Cancer Cell. 2016 Jun 30. pii: S1535-6108(16)30226-4. doi: 10.1016/j.ccell.2016.06.001. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer. Suzuki S1, Karayama M1,2, Inui N3,4, et al. Invest New Drugs. 2016 Aug;34(4):490-6. doi: 10.1007/s10637-016-0365-4. Epub 2016 Jun 9.

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adeno-carcinoma. Yoshiya T1, Mimae T1, Tsutani Y1, et al. Ann Thorac Surg. 2016 Jun 23. pii: S0003-4975(16)30419-2. doi: 10.1016/j.athoracsur.2016.04.087. [Epub ahead of print]

Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Deek MP1, Kim S, Ahmed I, Fang BS, Zou W, Malhotra J, Aisner J, Jabbour SK. Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print]

Brain metastases from non-small cell lung cancer: radiation therapy in the era of targeted therapies. Khalifa J1, Amini A2, Popat S3, Gaspar LE2, Faivre-Finn C4; IASLC Advanced Radiation Technology Committee. J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30519-6. doi: 10.1016/j.jtho.2016.06.002. [Epub ahead of print]

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. Yoshida T1, Oya Y2, Tanaka K2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO658732. [Epub ahead of print]

Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Zhang YC1,2, Zhou Q2, Wu YL2. Expert Opin Pharmacother. 2016 Jun 30. [Epub ahead of print]

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Bilen MA1, Patel A2, Hess KR3, et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):167-71. doi: 10.1007/s00280-016-3073-z. Epub 2016 Jun 10.

Safety of gefitinib in non-small cell lung cancer treatment. Hsiue EH1, Lee JH1,2,3,4, Lin CC1,3,4, Yang JC1,2,3,4. Expert Opin Drug Saf. 2016 Jul;15(7):993-1000. doi: 10.1080/14740338.2016.1192605. Epub 2016 Jun 7.

A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Yanagita M1, Redig AJ1, Paweletz CP2, et al. Clin Cancer Res. 2016 Jun 8. pii: clincanres.0909.2016. [Epub ahead of print]

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer. Wang E1, Nickens DJ2, Bello A3, Khosravan R4, Amantea M5, Wilner K6, Parivar K7, Tan W8. Clin Cancer Res. 2016 Jun 8. pii: clincanres.0536.2016. [Epub ahead of print]

Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery. Yang KL1, Chang YC2, Ko HL3, et al. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30129-2. doi: 10.1016/j.cllc.2016.05.013. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – IMMUNOTHERAPY

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Gettinger S1, Rizvi NA2, Chow LQ2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO669929. [Epub ahead of print]

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Rizvi NA1, Hellmann MD2, Brahmer JR2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO669861. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Characterizing spatiotemporal information loss in sparse-sampling-based dynamic MRI for monitoring respiration-induced tumor motion in radiotherapy. Arai TJ1, Nofiele J2, Madhuranthakam AJ3, Yuan Q2, Pedrosa I3, Chopra R3, Sawant A4. Med Phys. 2016 Jun;43(6):2807. doi: 10.1118/1.4948684.

Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer. Pollom EL1, Qian Y1, Durkee BY1, et al. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30140-1. doi: 10.1016/j.cllc.2016.05.024. [Epub ahead of print]

Patterns of loco-regional relapses in contemporarily staged stage III-N2 non-small cell lung cancer patients treated with induction chemotherapy and resection: Implications for postoperative radiotherapy target volumes. Billiet C1, De Ruysscher D2, Peeters S3, et al. J Thorac Oncol. 2016 Jun 30. pii: S1556-0864(16)30589-5. doi: 10.1016/j.jtho.2016.05.037. [Epub ahead of print]

Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Chaudhuri AA1, Binkley MS1, Rigdon J2, et al. Radiother Oncol. 2016 Jun;119(3):454-60. doi: 10.1016/j.radonc.2016.05.007. Epub 2016 Jun 3.

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Campo M1, Al-Halabi H2, Khandekar M2, Shaw AT3, Sequist LV3, Willers H4. Oncologist. 2016 Jun 27. pii: theoncologist.2015-0508. [Epub ahead of print]

Cost of Intensity-modulated Radiation Therapy for Older Stage III Lung Cancer Patients. Kale MS1, Mhango G2, Bonomi M3, Federman A4, Sigel K5, Rosenzweig KE6, Wisnivesky JP7. Ann Am Thorac Soc. 2016 Jun 14. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Smoking status and 30-day mortality in patients undergoing pulmonary resections. Mediratta N1, Poullis M2. Asian Cardiovasc Thorac Ann. 2016 Jun 30. pii: 0218492316657252. [Epub ahead of print]

Comparison of treatment outcomes between single-port video-assisted thoracoscopic anatomic segmentectomy and lobectomy for non-small cell lung cancer of early-stage: a retrospective observational study. Lin Y1, Zheng W1, Zhu Y1, Guo Z1, Zheng B1, Chen C1. J Thorac Dis. 2016 Jun;8(6):1290-6. doi: 10.21037/jtd.2016.04.65.

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy? Ma QL1, Guo YQ1, Shi B1, Tian YC1, Song ZY1, Liu DR1. J Thorac Dis. 2016 Jun;8(6):1227-33. doi: 10.21037/jtd.2016.04.60.

Physiologic assessment before video thoracoscopic resection for lung cancer in patients with abnormal pulmonary function. Benattia A1, Debeaumont D1, Guyader V1, Tardif C1, Peillon C1, Cuvelier A1, Baste JM1. J Thorac Dis. 2016 Jun;8(6):1170-8. doi: 10.21037/jtd.2016.04.38.

Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer. Johnson KK1, Rosen JE1, Salazar MC1, Boffa DJ2. Ann Thorac Surg. 2016 Jun 23. pii: S0003-4975(16)30418-0. doi: 10.1016/j.athoracsur.2016.04.086. [Epub ahead of print]

The Outcomes of a Limited Resection for Non-Small Cell Lung Cancer Based on Differences in Pathology. Yano M1, Yoshida J2, Koike T3, et al. World J Surg. 2016 Jun 30. [Epub ahead of print]

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer. Brown LM1, Louie BE2, Jackson N3, Farivar AS4, Aye RW4, Vallières E4. Ann Thorac Surg. 2016 Jun 24. pii: S0003-4975(16)30367-8. doi: 10.1016/j.athoracsur.2016.04.037. [Epub ahead of print]

Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale for Radiologic Follow-Up. Billè A1, Ahmad U2, Woo KM3, Suzuki K2, Adusumilli P2, Huang J2, Jones DR2, Rizk NP2. Ann Thorac Surg. 2016 Jun 24. pii: S0003-4975(16)30386-1. doi: 10.1016/j.athoracsur.2016.04.056. [Epub ahead of print]

Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Nishii T1,2, Yokose T2, Miyagi Y3, et al. Asia Pac J Clin Oncol. 2016 Jun 28. doi: 10.1111/ajco.12512. [Epub ahead of print]

Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Takada K1, Okamoto T2, Shoji F3, et al. J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30523-8. doi: 10.1016/j.jtho.2016.06.006. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Miao L1, Lu Y1, Xu Y1, Zhang G2, Huang Z1, Gong L1, Fan Y1. Oncotarget. 2016 Jun 1. doi: 10.18632/oncotarget.9765. [Epub ahead of print]

Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. Fernandez-Cuesta L1, Perdomo S2, Avogbe PH1, et al. EBioMedicine. 2016 Jun 25. pii: S2352-3964(16)30289-4. doi: 10.1016/j.ebiom.2016.06.032. [Epub ahead of print]

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Jahchan NS1, Lim JS1, Bola B2, et al. Cell Rep. 2016 Jun 29. pii: S2211-1247(16)30761-6. doi: 10.1016/j.celrep.2016.06.021. [Epub ahead of print]

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K1, Ohe Y2, Shibata T3, et al. Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30104-8. doi: 10.1016/S1470-2045(16)30104-8. [Epub ahead of print]

The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Horn L1, Reck M2, Spigel DR3. Oncologist. 2016 Jun 27. pii: theoncologist.2015-0523. [Epub ahead of print]

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Jahchan NS1, Lim JS1, Bola B2, et al. Cell Rep. 2016 Jun 29. pii: S2211-1247(16)30761-6. doi: 10.1016/j.celrep.2016.06.021. [Epub ahead of print]

Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. Hatfield LA1, Huskamp HA2, Lamont EB2. Oncol Pract. 2016 Jun 28. pii: JOPR012492. [Epub ahead of print]

Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. Arriola E1, Wheater M2, Galea I3, et al. J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30503-2. doi: 10.1016/j.jtho.2016.05.028. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

MISCELLANEOUS WORKS

Racial/Ethnic Disparities in Genomic Sequencing. Spratt DE1, Chan T2, Waldron L2, Speers C1, Feng FY1, Ogunwobi OO3, Osborne JR4. JAMA Oncol. 2016 Jun 30. doi: 10.1001/jamaoncol.2016.1854. [Epub ahead of print]

Beyond Traditional Newspaper Advertisement: Leveraging Facebook-Targeted Advertisement to Recruit Long-Term Smokers for Research. Carter-Harris L1, Bartlett Ellis R, Warrick A, Rawl S. J Med Internet Res. 2016 Jun 15;18(6):e117. doi: 10.2196/jmir.5502.

Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer. Williams CD1, Salama JK2, Moghanaki D3, Karas TZ4, Kelley MJ5. J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30505-6. doi: 10.1016/j.jtho.2016.05.030. [Epub ahead of print]

Cancer survivors’ experiences with insurance, finances, and employment: results from a multisite study. Nekhlyudov L1, Walker R2, Ziebell R2, Rabin B3,4,5, Nutt S6,7, Chubak J2. J Cancer Surviv. 2016 Jun 9. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Predictors of psychological distress in advanced cancer patients under palliative treatments. Diaz-Frutos D1,2,3, Baca-Garcia E1, García-Foncillas J2, López-Castroman J1,4. Eur J Cancer Care (Engl). 2016 Jul;25(4):608-15. doi: 10.1111/ecc.12521. Epub 2016 Jun 8.

Early and Intensive Dietary Counseling in Lung Cancer Patients Receiving (Chemo)Radiotherapy-A Pilot Randomized Controlled Trial. Kiss N1,2,3, Isenring E4,5, Gough K1, et al. Nutr Cancer. 2016 Jun 27:1-10. [Epub ahead of print]

Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT. Kim EY1, Kim YS2, Park I3, Ahn HK3, Cho EK3, Jeong YM1, Kim JH1. Support Care Cancer. 2016 Jun 30. [Epub ahead of print]

SCREENING, DIAGNOSIS AND STAGING

Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.  Raghunathan R1, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N. Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print]

Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples. Sanders H1, Qu K2, Li H2, et al. Mol Diagn Ther. 2016 Jun;20(3):241-53. doi: 10.1007/s40291-016-0197-0.

Safety and feasibility of prolonged bronchoscopy involving diagnosis of lung cancer, systematic nodal staging, and fiducial marker placement in a high-risk population. Kular H1, Mudambi L1, Lazarus DR1, Cornwell L1, Zhu A1, Casal RF1. J Thorac Dis. 2016 Jun;8(6):1132-8. doi: 10.21037/jtd.2016.04.06.

Perceptions and utilization of lung cancer screening among primary care physicians. Raz DJ1, Wu GX1, Consunji M1, et al. J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30527-5. doi: 10.1016/j.jtho.2016.06.010. [Epub ahead of print]

Integration of multiple “OMIC” biomarkers: A precision medicine strategy for lung cancer. Robles AI1, Harris CC2. Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30361-0. doi: 10.1016/j.lungcan.2016.06.003. [Epub ahead of print]

Comprehensive clinical staging for resectable lung cancer: Clinico-pathological correlations and the role of brain MRI. Vernon J1, Andruszkiewicz N2, Schneider L1, Schieman C1, Finley CJ1, Shargall Y1, Fahim C1, Farrokhyar F2, Hanna WC3. J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30520-2. doi: 10.1016/j.jtho.2016.06.003. [Epub ahead of print]

Validation of an Electronic Program for Pathologist Training in the Interpretation of a Complex Companion Diagnostic Immunohistochemical Assay. Dennis E1, Banks P2, Murata LB2, et al. Hum Pathol. 2016 Jun 24. pii: S0046-8177(16)30131-9. doi: 10.1016/j.humpath.2016.06.013. [Epub ahead of print]

Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians. Ersek JL1,2, Eberth JM1,3, McDonnell KK4, Strayer SM5, Sercy E3, Cartmell KB6, Friedman DB3,7. Cancer. 2016 Jun 13. doi: 10.1002/cncr.29944. [Epub ahead of print]

Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma. Makino T1, Mikami T2, Hata Y1, et al. Ann Thorac Surg. 2016 Jun 28. pii: S0003-4975(16)30481-7. doi: 10.1016/j.athoracsur.2016.04.100. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)